NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free CDT Stock Alerts $3.03 +0.19 (+6.69%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$2.83▼$3.2750-Day Range$2.82▼$3.6752-Week Range$0.95▼$25.00Volume126,365 shsAverage Volume35,597 shsMarket Capitalization$223.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Conduit Pharmaceuticals alerts: Email Address Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. About Conduit Pharmaceuticals Stock (NASDAQ:CDT)Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More CDT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDT Stock News HeadlinesMay 22, 2024 | businesswire.comAstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024May 15, 2024 | investorplace.comCDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 2024March 19, 2024 | finance.yahoo.comConduit Pharmaceuticals Adds Key Leadership PositionsMarch 19, 2024 | globenewswire.comConduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific OfficerMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Opens New Laboratory in UKMarch 11, 2024 | finance.yahoo.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences HubMarch 11, 2024 | globenewswire.comConduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences HubFebruary 28, 2024 | seekingalpha.comConduit Pharmaceuticals: Stellar Management Team, New Business ModelFebruary 15, 2024 | sg.finance.yahoo.comConduit Pharmaceuticals Inc. (CDT)February 13, 2024 | uk.finance.yahoo.comConduit Pharmaceuticals Inc. (CDTTW)January 31, 2024 | finance.yahoo.comConduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDecember 6, 2023 | wsj.comConduit Pharmaceuticals Inc.November 2, 2023 | finance.yahoo.comConduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare ConferenceOctober 31, 2023 | msn.comKXIN and ICU among pre-market losersOctober 28, 2023 | seekingalpha.comCDT Conduit Pharmaceuticals Inc.October 24, 2023 | uk.investing.comConduit Pharmaceuticals Inc (CDT)October 11, 2023 | finance.yahoo.comConduit Pharma CEO Tapolczay on Biopharma Differentiation, PipelineOctober 11, 2023 | finance.yahoo.comConduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656See More Headlines Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/28/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CUSIPN/A CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-20.19% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-303.00Miscellaneous Outstanding Shares73,830,000Free Float56,487,000Market Cap$223.70 million OptionableNot Optionable Beta2.52 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. David Joszef Tapolczay (Age 65)CEO & Director Comp: $419.8kMr. Adam Sragovicz (Age 54)Chief Financial Officer Comp: $116.67kDr. Joanne M. Holland (Age 49)Chief Scientific Officer Key CompetitorsCentessa PharmaceuticalsNASDAQ:CNTACureVacNASDAQ:CVACArcturus TherapeuticsNASDAQ:ARCT89bioNASDAQ:ETNBZentalis PharmaceuticalsNASDAQ:ZNTLView All Competitors CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed in 2024? Conduit Pharmaceuticals' stock was trading at $4.55 at the beginning of 2024. Since then, CDT shares have decreased by 33.4% and is now trading at $3.03. View the best growth stocks for 2024 here. Are investors shorting Conduit Pharmaceuticals? Conduit Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 34,100 shares, a decline of 19.8% from the April 30th total of 42,500 shares. Based on an average daily volume of 31,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.3% of the company's shares are short sold. View Conduit Pharmaceuticals' Short Interest. When is Conduit Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CDT earnings forecast. How were Conduit Pharmaceuticals' earnings last quarter? Conduit Pharmaceuticals Inc. (NASDAQ:CDT) posted its earnings results on Tuesday, May, 14th. The company reported ($0.05) EPS for the quarter. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDT) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.